136 results
6-K
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
, engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda focuses on six key business … fiscal year
AER
CER
Amount of Change
% Change
Revenue
Cost of sales
Selling, general and administrative expenses
Research and development expenses
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
expenses
Research and development expenses
Amortization and impairment losses on intangible assets associated with products
Other operating income
Other … ). The increase was mainly due to the depreciation of Japanese yen partially offset by various cost efficiencies.
Research and Development (R&D
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
CER
Amount of Change
% Change
Revenue
Cost of sales
Selling, general and administrative expenses
Research and development expenses
Amortization … yen partially offset by various cost efficiencies.
Research and Development (R&D) expenses
R&D expenses were JPY 534.1 billion (JPY +61.7 billion
6-K
TAK
Takeda Pharmaceutical Co
16 Jan 24
Current report (foreign)
6:01am
, President & CEO:
Christophe Weber
Representative Director, President:
Daisuke Izutsu
(4) Business description
Research and development
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
14 Dec 23
Current report (foreign)
6:01am
governance, environmental and social initiatives, corporate and financial strategy, research and development, capital policy, business performance … management policy, sustainability matters, managerial and financial strategies, research and development, capital policy, financial performance
6-K
EX-99.1
vjrmm 0chy
30 Nov 23
Current report (foreign)
6:01am
6-K
atszztd1om itd47
30 Oct 23
Current report (foreign)
6:02am
6-K
jsnyab
26 Oct 23
Current report (foreign)
6:20am
6-K
oeu9 12b4gu8r
1 Aug 23
Current report (foreign)
6:10am
6-K
5pw9cur5yok2egb
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
mdmmr2l0fclmh9
12 Jul 23
Current report (foreign)
6:07am
144
2wq6fryiq1
10 Jul 23
Notice of proposed sale of securities
6:09am
6-K
EX-99.1
aq2i1n
6 Jul 23
Current report (foreign)
6:18am
S-8
3pvmzsam
28 Jun 23
Registration of securities for employees
6:35am
6-K
EX-99.1
nnevd0s1gebn1pnyddvk
23 Jun 23
Current report (foreign)
6:13am
6-K
vk60duwu8ychxrqz
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
xj3eu8g092ekg9
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
1migc9pcttixg 54
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
g0moyxb3br8qos70uqmw
30 May 23
Current report (foreign)
6:11am